Your browser doesn't support javascript.
loading
Successful treatment of necrobiosis lipoidica and associated retinal vasculitis with tumor necrosis factor (TNF)-alpha inhibitor.
Panse, Ketaki; Herrera, Manuela; Fung, Maxwell; Brassard, Alain; Moussa, Kareem.
Afiliação
  • Panse K; Department of Ophthalmology & Vision Science, University of California, Davis, Sacramento, CA, USA.
  • Herrera M; University of California, Davis, School of Medicine, Sacramento, CA, USA.
  • Fung M; Department of Dermatology, University of California, Davis, Sacramento, CA, USA.
  • Brassard A; Department of Dermatology, University of California, Davis, Sacramento, CA, USA.
  • Moussa K; Department of Ophthalmology & Vision Science, University of California, Davis, Sacramento, CA, USA.
Am J Ophthalmol Case Rep ; 32: 101908, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37560554
ABSTRACT

Purpose:

To report the clinical and histopathologic features of necrobiosis lipoidica and associated retinal vasculitis and describe successful treatment of both skin and eye manifestations with adalimumab, a tumor necrosis factor (TNF)-alpha inhibitor. Observations A 35-year-old patient with bipolar disorder and ocular hypertension was referred for evaluation of bilateral retinal vasculitis. Fluorescein angiography revealed bilateral occlusive retinal vasculitis. Physical exam was notable for multiple annular and round erythematous hyperpigmented and atrophic patches and plaques on both lower extremities. Skin biopsy revealed a diagnosis of necrobiosis lipoidica, a rare granulomatous skin disease. Both the patient's retinal vasculitis and skin patches responded favorably to treatment with adalimumab, a TNF-alpha inhibitor. Conclusions and importance This case highlights the importance of obtaining a complete history and physical exam in patients who present with ocular inflammation, as extraocular manifestations of disease may be present. It also demonstrates the effectiveness of a multidisciplinary approach to evaluation and management of these patients, as both skin and eye involvement were successfully treated with adalimumab, a TNF-alpha inhibitor.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article